Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967168 | 0.76 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL14968159 | 0.76 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL14967689 | 0.75 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL26044135 | 0.70 | BTK (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL26064663 | 0.70 | BTK (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL16110089 | 0.69 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL571091 | 0.68 | MAPK1 (0.33) | MAPK1MEN1KMT2A | |
| SCHEMBL18616097 | 0.67 | BTK (0.46) | MAPK1MEN1KMT2A | |
| SCHEMBL14967324 | 0.66 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL29637311 | 0.66 | BTK (0.45) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| EP-3150617-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | CIPLA USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132768-A1 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132777-A2 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132770-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2217610-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | MAPK1 4319/4885MEN1 3085/4885KMT2A 3053/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | MAPK1 4319/4885MEN1 3085/4885KMT2A 3053/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | MAPK1 4319/4885MEN1 3085/4885KMT2A 3053/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | MAPK1 4319/4885MEN1 3085/4885KMT2A 3053/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | MAPK1 4319/4885MEN1 3085/4885KMT2A 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.